Hisun Pharmaceuticals

Hisun Pharmaceuticals USA, established in 2009 in Princeton, New Jersey, is a private, revenue-generating company that serves as the US commercial and strategic arm of its Chinese parent, Zhejiang Hisun Pharmaceutical. The company's core business model integrates the development and sale of generic drugs, APIs, and contract manufacturing, with a growing focus on specialty pharmaceuticals and novel technologies like Antibody Drug Conjugates (ADCs). Backed by a large, vertically integrated parent company with over 7,000 employees, Hisun USA aims to grow its presence in the competitive US generic and specialty drug markets through internal development, partnership, and acquisition.

Vertically integrated manufacturing platform for small molecule APIs, finished dosage forms, and biologics including Antibody Drug Conjugates (ADCs) and biosimilars, leveraged from its parent company.

Competes in generics against large global players like Teva, Sandoz, and Viatris, and in APIs against other major Chinese and Indian manufacturers. Its move into ADC manufacturing places it against established CDMOs like Lonza and Samsung Biologics, as well as innovator companies with internal capacity.